{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:08:23Z","timestamp":1779073703791,"version":"3.51.4"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the\n                    <jats:italic>CYPC2C19<\/jats:italic>\n                    gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, and more recently the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics. Despite this extensive guidance, pharmacogenetic information is rarely used to guide clopidogrel prescription in cardiology patients. The present study assesses the visibility of the pharmacogenetic guidelines in the cardiology literature. We analyzed citations of the clopidogrel pharmacogenetic guidelines in the cardiology literature and in the cardiology guidelines\/position statements on the treatment of acute coronary syndromes and stable coronary artery disease. Citations of these guidelines were found to be limited in the cardiology literature. Only 3 out of 19 cardiology guidelines\/position statements refer to the pharmacogenetic guidelines. 58% of the cardiology guidelines\/position statements mention clopidogrel pharmacogenetics but suggest that the use of pre\u2010emptive genotyping for\n                    <jats:italic>CYP2C19<\/jats:italic>\n                    variants to guide clopidogrel prescription is of limited clinical relevance. Genetically determined variation in clopidogrel efficacy has poor visibility in the cardiology literature and clinical guidelines. It is perceived to have limited benefits for clinical practice despite mounting evidence from randomized controlled trials and systematic reviews\/meta\u2010analyses.\n                  <\/jats:p>","DOI":"10.1111\/cts.70584","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:45:13Z","timestamp":1778557513000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-3832","authenticated-orcid":false,"given":"Cinzia","family":"Dello Russo","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool UK"},{"name":"Department of Translational Medicine and Surgery, Section of Pharmacology Universit\u00e0 Cattolica del Sacro Cuore \u2010 Fondazione Policlinico Universitario A. Gemelli, IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8236-3993","authenticated-orcid":false,"given":"Luigi","family":"Venetucci","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health The University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9163-8537","authenticated-orcid":false,"given":"Abisope","family":"Akintola","sequence":"additional","affiliation":[{"name":"Manchester Institute of Innovation Research, Alliance Manchester Business School The University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-5610","authenticated-orcid":false,"given":"Dimitri","family":"Gagliardi","sequence":"additional","affiliation":[{"name":"Manchester Institute of Innovation Research, Alliance Manchester Business School The University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie","family":"Ramlogan","sequence":"additional","affiliation":[{"name":"Manchester Institute of Innovation Research, Alliance Manchester Business School The University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7266","authenticated-orcid":false,"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and Surgery, Section of Pharmacology Universit\u00e0 Cattolica del Sacro Cuore \u2010 Fondazione Policlinico Universitario A. Gemelli, IRCCS  Rome Italy"},{"name":"The Wolfson Centre for Personalised Medicine, Centre for Drug Safety Science University of Liverpool  Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41576\u2010022\u201000572\u20108"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2024.06.020"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.234"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614133"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2758"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029132"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2526"},{"key":"e_1_2_10_10_1","unstructured":"\u201cThe ClinPGx Database \u201dhttps:\/\/www.clinpgx.org\/."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100573"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178945"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/pme.15.4"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(96)09457\u20103"},{"key":"e_1_2_10_15_1","unstructured":"Reuters(2024) https:\/\/www.reuters.com\/legal\/bristol\u2010myers\u2010sanofi\u2010liability\u2010hawaii\u2010plavix\u2010case\u2010grows\u2010916\u2010million\u20102024\u201005\u201022\/."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001112"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032248"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179349"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytac224"},{"key":"e_1_2_10_21_1","unstructured":"\u201cThe US Food and Drug Administration Website \u201dhttps:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020839. Plavix Drug Labels."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.132"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.105"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907096"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab836"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.34"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.578"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/17410541.5.5.471"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101013"},{"key":"e_1_2_10_30_1","first-page":"636","volume-title":"Strategica. Upscaling Digital Transformation in Business and Economy","author":"Caseiro J.","year":"2019"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4801"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.032"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073\u2010022\u201001149\u20100"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43058\u2010022\u201000315\u20100"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/14622416.2024.2392479"},{"key":"e_1_2_10_36_1","unstructured":"\u201cNHS England \u2010 National Genomics Education Programme \u2013 GeNotes \u201dhttps:\/\/www.genomicseducation.hee.nhs.uk\/genotes\/in\u2010the\u2010clinic\/presentation\u2010patient\u2010requiring\u2010mavacamten\u2010for\u2010the\u2010treatment\u2010of\u2010hypertrophic\u2010cardiomyopathy\/."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.051"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.08.725"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ\u2010D\u201017\u201000381"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.08.069"},{"key":"e_1_2_10_41_1","unstructured":"The European Medicines Agency Database \u201cEMA Recommendations on DPD Testing Prior To Treatment With Fluorouracil Capecitabine Tegafur And Flucytosine \u201dhttps:\/\/www.ema.europa.eu\/en\/news\/ema\u2010recommendations\u2010dpd\u2010testing\u2010prior\u2010treatment\u2010fluorouracil\u2010capecitabine\u2010tegafur\u2010and\u2010flucytosine."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101197"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70057"},{"key":"e_1_2_10_44_1","article-title":"CYP2C19 Genotype Testing to Guide Clopidogrel Use After Ischaemic Stroke or Transient Ischaemic Attack","author":"The National Institute for Health and Care Excellence (NICE) Database","journal-title":"Diagnostics Guidance"},{"key":"e_1_2_10_45_1","unstructured":"The Medicine & Healthcare products Regulatory Agency (MHRA) Database \u201cSummary of Product Characteristics Approved by the MHRA for the Use of Mavacamten \u201dhttps:\/\/products.mhra.gov.uk\/search\/?search=mavacamten&page=1&doc=Spc&rerouteType=0."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70363"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70370"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.038"},{"key":"e_1_2_10_49_1","volume-title":"Personalised Prescribing: Using Pharmacogenomics to Improve Patient Outcomes","author":"Royal College of Physicians and British Pharmacological Society","year":"2022"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2023.07.012"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70584","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T02:53:42Z","timestamp":1779072822000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/cts.70584"],"URL":"https:\/\/doi.org\/10.1111\/cts.70584","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70584"}}